Posts by Sandra Ansanay-Alex

Merck invests into Cadribine to try to cure rare neuroinflammatory diseases   Chord Therapeutics (Chord), a clinical-stage biopharmaceutical company developing drugs for rare neuroinflammatory diseases, announced on 20 December 2021, that it has been acquired by the leading science and technology company Merck. The strategic acquisition enables Merck to expand its neurology pipeline to develop…